We are developing a robust pipeline of novel therapeutics that will soon transform treatment options for patients with systemic inflammatory diseases.

SBI-101 integrates into existing treatment modalities, enhancing the standard of care. Sentien’s technology has now been tested in numerous preclinical models and, in each case, overall survival was increased relative to controls. Our first in-human study is designed to assess safety and identify biomarker signatures for inflammation associated with Dialysis-Requiring Acute Kidney Injury (AKI-D). We are also working to build upon this foundation to address additional acute and chronic indications characterized by systemic inflammation.